Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LD02GIFRO
- Development stage
- Phase 2
- Lead developer
- LG Chem
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LD02GIFRO is a novel prokinetic agent formulated from the fruits of *Poncirus fructus* and *Zanthoxylum* species. It has been investigated for its effects on gastrointestinal motility, particularly in models of functional gastrointestinal disorders such as delayed gastric emptying and postoperative ileus. The formulation leverages traditional medicinal uses of its botanical components, which are known to influence abnormal gastrointestinal motility and gastric secretion. The precise molecular mechanism of action is not fully elucidated but is believed to involve modulation of gut motility pathways[1][2][3][4][7].
02
Targets
HTR4 (5-Hydroxytryptamine receptor 4)mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on LD02GIFRO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LD02GIFRO.